Kofarest-PD Syrup is a combination expectorant and bronchodilator formulation containing Ambroxol (15mg/5ml), Guaifenesin (50mg/5ml), and Terbutaline (1.25mg/5ml). Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus from the respiratory tract, thereby improving airway patency. Guaifenesin serves as an expectorant, promoting the loosening and thinning of mucus, which aids in productive cough and enhances mucus clearance. Terbutaline, a selective beta-2 adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, leading to improved airflow and relief from bronchospasm. This synergistic combination is indicated for the symptomatic relief of respiratory conditions characterized by excessive or thick mucus production and bronchoconstriction, such as acute and chronic bronchitis, asthma, and other obstructive airway diseases. Kofarest-PD Syrup is administered orally and is suitable for pediatric and adult patients under medical supervision. Caution is advised in patients with cardiovascular disorders, hyperthyroidism, or hypersensitivity to any component. Common adverse effects may include tachycardia, tremors, gastrointestinal disturbances, and allergic reactions. Use should be guided by a healthcare professional to ensure appropriate dosing and monitoring for efficacy and safety.